nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—BTK—Mitoxantrone—lymphatic system cancer	0.425	0.585	CbGbCtD
Dasatinib—CYP1B1—Mitoxantrone—lymphatic system cancer	0.0673	0.0926	CbGbCtD
Dasatinib—ABCG2—Teniposide—lymphatic system cancer	0.0458	0.063	CbGbCtD
Dasatinib—ABCG2—Mitoxantrone—lymphatic system cancer	0.032	0.044	CbGbCtD
Dasatinib—CYP1A2—Carmustine—lymphatic system cancer	0.0281	0.0386	CbGbCtD
Dasatinib—CYP3A5—Teniposide—lymphatic system cancer	0.0253	0.0349	CbGbCtD
Dasatinib—ABCG2—Vincristine—lymphatic system cancer	0.022	0.0303	CbGbCtD
Dasatinib—ABCG2—Methotrexate—lymphatic system cancer	0.0133	0.0183	CbGbCtD
Dasatinib—CYP3A5—Vincristine—lymphatic system cancer	0.0122	0.0168	CbGbCtD
Dasatinib—ABCB1—Mitoxantrone—lymphatic system cancer	0.0115	0.0159	CbGbCtD
Dasatinib—CYP3A4—Cytarabine—lymphatic system cancer	0.01	0.0138	CbGbCtD
Dasatinib—CYP3A4—Teniposide—lymphatic system cancer	0.00988	0.0136	CbGbCtD
Dasatinib—ABCB1—Vincristine—lymphatic system cancer	0.00794	0.0109	CbGbCtD
Dasatinib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00691	0.00951	CbGbCtD
Dasatinib—MYT1—Mecp2 and Associated Rett Syndrome—BCL6—lymphatic system cancer	0.00602	0.213	CbGpPWpGaD
Dasatinib—ABCB1—Methotrexate—lymphatic system cancer	0.00481	0.00662	CbGbCtD
Dasatinib—CYP3A4—Vincristine—lymphatic system cancer	0.00476	0.00655	CbGbCtD
Dasatinib—TEC—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.00385	0.136	CbGpPWpGaD
Dasatinib—ERBB3—Podofilox—Teniposide—lymphatic system cancer	0.00311	0.71	CbGdCrCtD
Dasatinib—CSF1R—Differentiation Pathway—ALK—lymphatic system cancer	0.00294	0.104	CbGpPWpGaD
Dasatinib—SIK1—Circadian rythm related genes—PROX1—lymphatic system cancer	0.00228	0.0809	CbGpPWpGaD
Dasatinib—STAT5B—IL4-mediated signaling events—BCL6—lymphatic system cancer	0.00176	0.0623	CbGpPWpGaD
Dasatinib—KIT—Differentiation Pathway—ALK—lymphatic system cancer	0.00147	0.052	CbGpPWpGaD
Dasatinib—ERBB3—Vinblastine—Vincristine—lymphatic system cancer	0.00127	0.29	CbGdCrCtD
Dasatinib—BTK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.00106	0.0376	CbGpPWpGaD
Dasatinib—BLK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000882	0.0313	CbGpPWpGaD
Dasatinib—EPHA2—Direct p53 effectors—BCL6—lymphatic system cancer	0.000865	0.0307	CbGpPWpGaD
Dasatinib—MAPK14—IL4-mediated signaling events—BCL6—lymphatic system cancer	0.000718	0.0254	CbGpPWpGaD
Dasatinib—JAK2—IL4-mediated signaling events—BCL6—lymphatic system cancer	0.000709	0.0251	CbGpPWpGaD
Dasatinib—LYN—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000529	0.0188	CbGpPWpGaD
Dasatinib—FYN—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000521	0.0185	CbGpPWpGaD
Dasatinib—MAPK14—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000502	0.0178	CbGpPWpGaD
Dasatinib—HCK—Host Interactions of HIV factors—NPM1—lymphatic system cancer	0.0005	0.0177	CbGpPWpGaD
Dasatinib—ABL1—DNA Damage Response (only ATM dependent)—BCL6—lymphatic system cancer	0.00048	0.017	CbGpPWpGaD
Dasatinib—LCK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000434	0.0154	CbGpPWpGaD
Dasatinib—ABCG2—HIF-1-alpha transcription factor network—NPM1—lymphatic system cancer	0.000362	0.0128	CbGpPWpGaD
Dasatinib—HCK—HIV Infection—NPM1—lymphatic system cancer	0.000325	0.0115	CbGpPWpGaD
Dasatinib—FYN—Host Interactions of HIV factors—NPM1—lymphatic system cancer	0.000267	0.00947	CbGpPWpGaD
Dasatinib—PKMYT1—Cell Cycle—NPM1—lymphatic system cancer	0.000258	0.00915	CbGpPWpGaD
Dasatinib—Body temperature increased—Fludarabine—lymphatic system cancer	0.000256	0.00106	CcSEcCtD
Dasatinib—Mental disorder—Carmustine—lymphatic system cancer	0.000256	0.00106	CcSEcCtD
Dasatinib—Erythema—Carmustine—lymphatic system cancer	0.000254	0.00105	CcSEcCtD
Dasatinib—Malnutrition—Carmustine—lymphatic system cancer	0.000254	0.00105	CcSEcCtD
Dasatinib—Cough—Bleomycin—lymphatic system cancer	0.000254	0.00105	CcSEcCtD
Dasatinib—Angiopathy—Vincristine—lymphatic system cancer	0.000253	0.00105	CcSEcCtD
Dasatinib—Diarrhoea—Teniposide—lymphatic system cancer	0.000252	0.00105	CcSEcCtD
Dasatinib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000251	0.00104	CcSEcCtD
Dasatinib—Chest pain—Bleomycin—lymphatic system cancer	0.000248	0.00103	CcSEcCtD
Dasatinib—Myalgia—Bleomycin—lymphatic system cancer	0.000248	0.00103	CcSEcCtD
Dasatinib—Alopecia—Vincristine—lymphatic system cancer	0.000246	0.00102	CcSEcCtD
Dasatinib—Discomfort—Bleomycin—lymphatic system cancer	0.000245	0.00102	CcSEcCtD
Dasatinib—Mental disorder—Vincristine—lymphatic system cancer	0.000244	0.00101	CcSEcCtD
Dasatinib—Chills—Mitoxantrone—lymphatic system cancer	0.000243	0.00101	CcSEcCtD
Dasatinib—Ecchymosis—Methotrexate—lymphatic system cancer	0.000243	0.00101	CcSEcCtD
Dasatinib—Neoplasm—Methotrexate—lymphatic system cancer	0.000243	0.00101	CcSEcCtD
Dasatinib—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000242	0.00101	CcSEcCtD
Dasatinib—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000241	0.001	CcSEcCtD
Dasatinib—Alopecia—Mitoxantrone—lymphatic system cancer	0.00024	0.000995	CcSEcCtD
Dasatinib—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000239	0.000995	CcSEcCtD
Dasatinib—Confusional state—Bleomycin—lymphatic system cancer	0.000239	0.000994	CcSEcCtD
Dasatinib—Vision blurred—Carmustine—lymphatic system cancer	0.000239	0.000994	CcSEcCtD
Dasatinib—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000239	0.000991	CcSEcCtD
Dasatinib—Tremor—Carmustine—lymphatic system cancer	0.000238	0.000988	CcSEcCtD
Dasatinib—Oedema—Bleomycin—lymphatic system cancer	0.000237	0.000986	CcSEcCtD
Dasatinib—Erythema—Mitoxantrone—lymphatic system cancer	0.000236	0.00098	CcSEcCtD
Dasatinib—Infection—Bleomycin—lymphatic system cancer	0.000236	0.00098	CcSEcCtD
Dasatinib—Anaemia—Carmustine—lymphatic system cancer	0.000235	0.000975	CcSEcCtD
Dasatinib—Vomiting—Teniposide—lymphatic system cancer	0.000234	0.000973	CcSEcCtD
Dasatinib—Sepsis—Methotrexate—lymphatic system cancer	0.000233	0.00097	CcSEcCtD
Dasatinib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000232	0.000965	CcSEcCtD
Dasatinib—Asthenia—Fludarabine—lymphatic system cancer	0.000232	0.000965	CcSEcCtD
Dasatinib—Rash—Teniposide—lymphatic system cancer	0.000232	0.000965	CcSEcCtD
Dasatinib—Dermatitis—Teniposide—lymphatic system cancer	0.000232	0.000964	CcSEcCtD
Dasatinib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000231	0.00096	CcSEcCtD
Dasatinib—Headache—Teniposide—lymphatic system cancer	0.000231	0.000959	CcSEcCtD
Dasatinib—Pruritus—Fludarabine—lymphatic system cancer	0.000229	0.000951	CcSEcCtD
Dasatinib—Anorexia—Bleomycin—lymphatic system cancer	0.000226	0.00094	CcSEcCtD
Dasatinib—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000226	0.000937	CcSEcCtD
Dasatinib—Anaemia—Vincristine—lymphatic system cancer	0.000224	0.00093	CcSEcCtD
Dasatinib—LCK—Host Interactions of HIV factors—NPM1—lymphatic system cancer	0.000223	0.00789	CbGpPWpGaD
Dasatinib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000222	0.000924	CcSEcCtD
Dasatinib—Photosensitivity—Methotrexate—lymphatic system cancer	0.000222	0.000924	CcSEcCtD
Dasatinib—Hypotension—Bleomycin—lymphatic system cancer	0.000222	0.000921	CcSEcCtD
Dasatinib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000222	0.00092	CcSEcCtD
Dasatinib—Convulsion—Carmustine—lymphatic system cancer	0.00022	0.000914	CcSEcCtD
Dasatinib—Hypertension—Carmustine—lymphatic system cancer	0.000219	0.00091	CcSEcCtD
Dasatinib—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000219	0.00091	CcSEcCtD
Dasatinib—Nausea—Teniposide—lymphatic system cancer	0.000219	0.000909	CcSEcCtD
Dasatinib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000218	0.000906	CcSEcCtD
Dasatinib—Vertigo—Vincristine—lymphatic system cancer	0.000218	0.000904	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000216	0.000898	CcSEcCtD
Dasatinib—Chest pain—Carmustine—lymphatic system cancer	0.000216	0.000898	CcSEcCtD
Dasatinib—Myalgia—Carmustine—lymphatic system cancer	0.000216	0.000898	CcSEcCtD
Dasatinib—Anxiety—Carmustine—lymphatic system cancer	0.000215	0.000895	CcSEcCtD
Dasatinib—Malaise—Mitoxantrone—lymphatic system cancer	0.000213	0.000884	CcSEcCtD
Dasatinib—Dyspnoea—Bleomycin—lymphatic system cancer	0.000212	0.000879	CcSEcCtD
Dasatinib—Convulsion—Vincristine—lymphatic system cancer	0.00021	0.000872	CcSEcCtD
Dasatinib—Hypertension—Vincristine—lymphatic system cancer	0.000209	0.000869	CcSEcCtD
Dasatinib—Confusional state—Carmustine—lymphatic system cancer	0.000209	0.000868	CcSEcCtD
Dasatinib—Oedema—Carmustine—lymphatic system cancer	0.000207	0.000861	CcSEcCtD
Dasatinib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000206	0.000857	CcSEcCtD
Dasatinib—Myalgia—Vincristine—lymphatic system cancer	0.000206	0.000857	CcSEcCtD
Dasatinib—Visual disturbance—Methotrexate—lymphatic system cancer	0.000206	0.000856	CcSEcCtD
Dasatinib—Cough—Mitoxantrone—lymphatic system cancer	0.000206	0.000856	CcSEcCtD
Dasatinib—Infection—Carmustine—lymphatic system cancer	0.000206	0.000855	CcSEcCtD
Dasatinib—Vomiting—Fludarabine—lymphatic system cancer	0.000206	0.000855	CcSEcCtD
Dasatinib—Convulsion—Mitoxantrone—lymphatic system cancer	0.000205	0.000849	CcSEcCtD
Dasatinib—Rash—Fludarabine—lymphatic system cancer	0.000204	0.000848	CcSEcCtD
Dasatinib—Dermatitis—Fludarabine—lymphatic system cancer	0.000204	0.000847	CcSEcCtD
Dasatinib—Hypertension—Mitoxantrone—lymphatic system cancer	0.000204	0.000846	CcSEcCtD
Dasatinib—Pain—Bleomycin—lymphatic system cancer	0.000203	0.000843	CcSEcCtD
Dasatinib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000203	0.000843	CcSEcCtD
Dasatinib—Headache—Fludarabine—lymphatic system cancer	0.000203	0.000842	CcSEcCtD
Dasatinib—Tachycardia—Carmustine—lymphatic system cancer	0.000202	0.00084	CcSEcCtD
Dasatinib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000201	0.000835	CcSEcCtD
Dasatinib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000201	0.000835	CcSEcCtD
Dasatinib—Chest pain—Mitoxantrone—lymphatic system cancer	0.000201	0.000835	CcSEcCtD
Dasatinib—Anxiety—Mitoxantrone—lymphatic system cancer	0.0002	0.000832	CcSEcCtD
Dasatinib—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000199	0.000828	CcSEcCtD
Dasatinib—Discomfort—Mitoxantrone—lymphatic system cancer	0.000199	0.000825	CcSEcCtD
Dasatinib—Oedema—Vincristine—lymphatic system cancer	0.000198	0.000822	CcSEcCtD
Dasatinib—Anorexia—Carmustine—lymphatic system cancer	0.000198	0.00082	CcSEcCtD
Dasatinib—Infection—Vincristine—lymphatic system cancer	0.000197	0.000816	CcSEcCtD
Dasatinib—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000196	0.000813	CcSEcCtD
Dasatinib—ABCB1—HIF-1-alpha transcription factor network—NPM1—lymphatic system cancer	0.000196	0.00693	CbGpPWpGaD
Dasatinib—Confusional state—Mitoxantrone—lymphatic system cancer	0.000194	0.000807	CcSEcCtD
Dasatinib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000194	0.000806	CcSEcCtD
Dasatinib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000194	0.000804	CcSEcCtD
Dasatinib—Hypotension—Carmustine—lymphatic system cancer	0.000194	0.000804	CcSEcCtD
Dasatinib—Oedema—Mitoxantrone—lymphatic system cancer	0.000193	0.0008	CcSEcCtD
Dasatinib—Nausea—Fludarabine—lymphatic system cancer	0.000192	0.000799	CcSEcCtD
Dasatinib—Infection—Mitoxantrone—lymphatic system cancer	0.000191	0.000795	CcSEcCtD
Dasatinib—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000191	0.000794	CcSEcCtD
Dasatinib—Shock—Mitoxantrone—lymphatic system cancer	0.00019	0.000787	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000189	0.000784	CcSEcCtD
Dasatinib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000189	0.000783	CcSEcCtD
Dasatinib—Urticaria—Bleomycin—lymphatic system cancer	0.000189	0.000783	CcSEcCtD
Dasatinib—Anorexia—Vincristine—lymphatic system cancer	0.000189	0.000783	CcSEcCtD
Dasatinib—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000188	0.000781	CcSEcCtD
Dasatinib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000188	0.000779	CcSEcCtD
Dasatinib—Insomnia—Carmustine—lymphatic system cancer	0.000187	0.000778	CcSEcCtD
Dasatinib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000187	0.000777	CcSEcCtD
Dasatinib—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000186	0.000774	CcSEcCtD
Dasatinib—Hypotension—Vincristine—lymphatic system cancer	0.000185	0.000768	CcSEcCtD
Dasatinib—Dyspnoea—Carmustine—lymphatic system cancer	0.000185	0.000767	CcSEcCtD
Dasatinib—Somnolence—Carmustine—lymphatic system cancer	0.000184	0.000765	CcSEcCtD
Dasatinib—Anorexia—Mitoxantrone—lymphatic system cancer	0.000184	0.000763	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00018	0.000749	CcSEcCtD
Dasatinib—Decreased appetite—Carmustine—lymphatic system cancer	0.00018	0.000748	CcSEcCtD
Dasatinib—Hypotension—Mitoxantrone—lymphatic system cancer	0.00018	0.000748	CcSEcCtD
Dasatinib—Insomnia—Vincristine—lymphatic system cancer	0.000179	0.000743	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000179	0.000743	CcSEcCtD
Dasatinib—Pain—Carmustine—lymphatic system cancer	0.000177	0.000736	CcSEcCtD
Dasatinib—Constipation—Carmustine—lymphatic system cancer	0.000177	0.000736	CcSEcCtD
Dasatinib—Breast disorder—Methotrexate—lymphatic system cancer	0.000176	0.000733	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000176	0.000729	CcSEcCtD
Dasatinib—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000175	0.000726	CcSEcCtD
Dasatinib—FYN—HIV Infection—NPM1—lymphatic system cancer	0.000174	0.00616	CbGpPWpGaD
Dasatinib—Decreased appetite—Vincristine—lymphatic system cancer	0.000172	0.000714	CcSEcCtD
Dasatinib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000172	0.000713	CcSEcCtD
Dasatinib—Somnolence—Mitoxantrone—lymphatic system cancer	0.000171	0.000711	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000171	0.000709	CcSEcCtD
Dasatinib—Feeling abnormal—Carmustine—lymphatic system cancer	0.000171	0.000709	CcSEcCtD
Dasatinib—Fatigue—Vincristine—lymphatic system cancer	0.000171	0.000708	CcSEcCtD
Dasatinib—Asthenia—Bleomycin—lymphatic system cancer	0.00017	0.000707	CcSEcCtD
Dasatinib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00017	0.000704	CcSEcCtD
Dasatinib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000169	0.000704	CcSEcCtD
Dasatinib—Pain—Vincristine—lymphatic system cancer	0.000169	0.000703	CcSEcCtD
Dasatinib—Constipation—Vincristine—lymphatic system cancer	0.000169	0.000703	CcSEcCtD
Dasatinib—Asthma—Methotrexate—lymphatic system cancer	0.000169	0.000701	CcSEcCtD
Dasatinib—Pruritus—Bleomycin—lymphatic system cancer	0.000168	0.000698	CcSEcCtD
Dasatinib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000167	0.000696	CcSEcCtD
Dasatinib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000166	0.00069	CcSEcCtD
Dasatinib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000165	0.000687	CcSEcCtD
Dasatinib—Pain—Mitoxantrone—lymphatic system cancer	0.000165	0.000684	CcSEcCtD
Dasatinib—Constipation—Mitoxantrone—lymphatic system cancer	0.000165	0.000684	CcSEcCtD
Dasatinib—Abdominal pain—Carmustine—lymphatic system cancer	0.000164	0.00068	CcSEcCtD
Dasatinib—Body temperature increased—Carmustine—lymphatic system cancer	0.000164	0.00068	CcSEcCtD
Dasatinib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000162	0.000672	CcSEcCtD
Dasatinib—Pancytopenia—Methotrexate—lymphatic system cancer	0.00016	0.000666	CcSEcCtD
Dasatinib—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000159	0.000659	CcSEcCtD
Dasatinib—Neutropenia—Methotrexate—lymphatic system cancer	0.000158	0.000656	CcSEcCtD
Dasatinib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000158	0.000654	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000157	0.000652	CcSEcCtD
Dasatinib—Abdominal pain—Vincristine—lymphatic system cancer	0.000156	0.000649	CcSEcCtD
Dasatinib—Body temperature increased—Vincristine—lymphatic system cancer	0.000156	0.000649	CcSEcCtD
Dasatinib—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000154	0.00064	CcSEcCtD
Dasatinib—Urticaria—Mitoxantrone—lymphatic system cancer	0.000153	0.000636	CcSEcCtD
Dasatinib—Hypersensitivity—Carmustine—lymphatic system cancer	0.000153	0.000634	CcSEcCtD
Dasatinib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000152	0.000633	CcSEcCtD
Dasatinib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000152	0.000633	CcSEcCtD
Dasatinib—Pneumonia—Methotrexate—lymphatic system cancer	0.000151	0.000629	CcSEcCtD
Dasatinib—Vomiting—Bleomycin—lymphatic system cancer	0.000151	0.000627	CcSEcCtD
Dasatinib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000151	0.000625	CcSEcCtD
Dasatinib—Infestation—Methotrexate—lymphatic system cancer	0.000151	0.000625	CcSEcCtD
Dasatinib—Rash—Bleomycin—lymphatic system cancer	0.00015	0.000622	CcSEcCtD
Dasatinib—Dermatitis—Bleomycin—lymphatic system cancer	0.00015	0.000621	CcSEcCtD
Dasatinib—Asthenia—Carmustine—lymphatic system cancer	0.000149	0.000618	CcSEcCtD
Dasatinib—Renal failure—Methotrexate—lymphatic system cancer	0.000148	0.000614	CcSEcCtD
Dasatinib—Stomatitis—Methotrexate—lymphatic system cancer	0.000147	0.000609	CcSEcCtD
Dasatinib—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000146	0.000608	CcSEcCtD
Dasatinib—Hypersensitivity—Vincristine—lymphatic system cancer	0.000146	0.000605	CcSEcCtD
Dasatinib—LCK—HIV Infection—NPM1—lymphatic system cancer	0.000145	0.00512	CbGpPWpGaD
Dasatinib—Haematuria—Methotrexate—lymphatic system cancer	0.000143	0.000596	CcSEcCtD
Dasatinib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000142	0.000591	CcSEcCtD
Dasatinib—Epistaxis—Methotrexate—lymphatic system cancer	0.000142	0.00059	CcSEcCtD
Dasatinib—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000142	0.00059	CcSEcCtD
Dasatinib—Asthenia—Vincristine—lymphatic system cancer	0.000142	0.000589	CcSEcCtD
Dasatinib—Diarrhoea—Carmustine—lymphatic system cancer	0.000142	0.000589	CcSEcCtD
Dasatinib—Nausea—Bleomycin—lymphatic system cancer	0.000141	0.000586	CcSEcCtD
Dasatinib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000138	0.000574	CcSEcCtD
Dasatinib—Dizziness—Carmustine—lymphatic system cancer	0.000137	0.000569	CcSEcCtD
Dasatinib—Haemoglobin—Methotrexate—lymphatic system cancer	0.000136	0.000564	CcSEcCtD
Dasatinib—Diarrhoea—Vincristine—lymphatic system cancer	0.000135	0.000562	CcSEcCtD
Dasatinib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000135	0.000561	CcSEcCtD
Dasatinib—Hepatitis—Methotrexate—lymphatic system cancer	0.000135	0.000561	CcSEcCtD
Dasatinib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000133	0.000554	CcSEcCtD
Dasatinib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000132	0.00055	CcSEcCtD
Dasatinib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000132	0.000547	CcSEcCtD
Dasatinib—Vomiting—Carmustine—lymphatic system cancer	0.000132	0.000547	CcSEcCtD
Dasatinib—Dizziness—Vincristine—lymphatic system cancer	0.000131	0.000543	CcSEcCtD
Dasatinib—Rash—Carmustine—lymphatic system cancer	0.000131	0.000543	CcSEcCtD
Dasatinib—Dermatitis—Carmustine—lymphatic system cancer	0.000131	0.000542	CcSEcCtD
Dasatinib—Visual impairment—Methotrexate—lymphatic system cancer	0.00013	0.000541	CcSEcCtD
Dasatinib—Headache—Carmustine—lymphatic system cancer	0.00013	0.000539	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000128	0.000531	CcSEcCtD
Dasatinib—Eye disorder—Methotrexate—lymphatic system cancer	0.000126	0.000524	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—lymphatic system cancer	0.000126	0.000523	CcSEcCtD
Dasatinib—Vomiting—Vincristine—lymphatic system cancer	0.000126	0.000522	CcSEcCtD
Dasatinib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000125	0.000521	CcSEcCtD
Dasatinib—Rash—Vincristine—lymphatic system cancer	0.000125	0.000518	CcSEcCtD
Dasatinib—Dermatitis—Vincristine—lymphatic system cancer	0.000125	0.000518	CcSEcCtD
Dasatinib—Headache—Vincristine—lymphatic system cancer	0.000124	0.000515	CcSEcCtD
Dasatinib—Nausea—Carmustine—lymphatic system cancer	0.000123	0.000511	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—lymphatic system cancer	0.000123	0.000509	CcSEcCtD
Dasatinib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000122	0.000509	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—lymphatic system cancer	0.000122	0.000507	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000122	0.000506	CcSEcCtD
Dasatinib—Rash—Mitoxantrone—lymphatic system cancer	0.000121	0.000505	CcSEcCtD
Dasatinib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000121	0.000504	CcSEcCtD
Dasatinib—Chills—Methotrexate—lymphatic system cancer	0.000121	0.000503	CcSEcCtD
Dasatinib—Headache—Mitoxantrone—lymphatic system cancer	0.000121	0.000501	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—lymphatic system cancer	0.000119	0.000496	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—lymphatic system cancer	0.000118	0.000492	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—lymphatic system cancer	0.000118	0.000488	CcSEcCtD
Dasatinib—Erythema—Methotrexate—lymphatic system cancer	0.000118	0.000488	CcSEcCtD
Dasatinib—Nausea—Vincristine—lymphatic system cancer	0.000118	0.000488	CcSEcCtD
Dasatinib—MAPK14—Gene Expression—RRP8—lymphatic system cancer	0.000115	0.00408	CbGpPWpGaD
Dasatinib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000115	0.000478	CcSEcCtD
Dasatinib—Nausea—Mitoxantrone—lymphatic system cancer	0.000114	0.000475	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—lymphatic system cancer	0.000111	0.00046	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000109	0.000453	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—lymphatic system cancer	0.000109	0.000451	CcSEcCtD
Dasatinib—Malaise—Methotrexate—lymphatic system cancer	0.000106	0.00044	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—lymphatic system cancer	0.000106	0.000439	CcSEcCtD
Dasatinib—CSK—Disease—NPM1—lymphatic system cancer	0.000104	0.00367	CbGpPWpGaD
Dasatinib—Cough—Methotrexate—lymphatic system cancer	0.000103	0.000426	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—lymphatic system cancer	0.000102	0.000423	CcSEcCtD
Dasatinib—STAT5B—Disease—NPM1—lymphatic system cancer	0.0001	0.00356	CbGpPWpGaD
Dasatinib—Myalgia—Methotrexate—lymphatic system cancer	0.0001	0.000416	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—lymphatic system cancer	0.0001	0.000416	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—lymphatic system cancer	0.0001	0.000416	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	9.94e-05	0.000413	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—lymphatic system cancer	9.89e-05	0.000411	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—lymphatic system cancer	9.68e-05	0.000402	CcSEcCtD
Dasatinib—Infection—Methotrexate—lymphatic system cancer	9.54e-05	0.000396	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—lymphatic system cancer	9.41e-05	0.000391	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—lymphatic system cancer	9.4e-05	0.00039	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—lymphatic system cancer	9.32e-05	0.000387	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—lymphatic system cancer	9.28e-05	0.000385	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—lymphatic system cancer	9.15e-05	0.00038	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—lymphatic system cancer	8.97e-05	0.000373	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	8.75e-05	0.000363	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—lymphatic system cancer	8.68e-05	0.000361	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—lymphatic system cancer	8.56e-05	0.000355	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—lymphatic system cancer	8.53e-05	0.000354	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—lymphatic system cancer	8.45e-05	0.000351	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—lymphatic system cancer	8.34e-05	0.000347	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	8.29e-05	0.000344	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—lymphatic system cancer	8.28e-05	0.000344	CcSEcCtD
Dasatinib—Pain—Methotrexate—lymphatic system cancer	8.21e-05	0.000341	CcSEcCtD
Dasatinib—HCK—Disease—NPM1—lymphatic system cancer	7.95e-05	0.00282	CbGpPWpGaD
Dasatinib—Feeling abnormal—Methotrexate—lymphatic system cancer	7.91e-05	0.000329	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	7.85e-05	0.000326	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—lymphatic system cancer	7.63e-05	0.000317	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—lymphatic system cancer	7.59e-05	0.000315	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—lymphatic system cancer	7.59e-05	0.000315	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—lymphatic system cancer	7.07e-05	0.000294	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—lymphatic system cancer	6.89e-05	0.000286	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—lymphatic system cancer	6.79e-05	0.000282	CcSEcCtD
Dasatinib—ERBB3—Disease—NPM1—lymphatic system cancer	6.61e-05	0.00234	CbGpPWpGaD
Dasatinib—Diarrhoea—Methotrexate—lymphatic system cancer	6.57e-05	0.000273	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—lymphatic system cancer	6.35e-05	0.000264	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—lymphatic system cancer	6.1e-05	0.000253	CcSEcCtD
Dasatinib—Rash—Methotrexate—lymphatic system cancer	6.05e-05	0.000251	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—lymphatic system cancer	6.05e-05	0.000251	CcSEcCtD
Dasatinib—Headache—Methotrexate—lymphatic system cancer	6.01e-05	0.00025	CcSEcCtD
Dasatinib—Nausea—Methotrexate—lymphatic system cancer	5.7e-05	0.000237	CcSEcCtD
Dasatinib—KIT—Disease—NPM1—lymphatic system cancer	5.18e-05	0.00183	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—NPM1—lymphatic system cancer	4.9e-05	0.00174	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NPM1—lymphatic system cancer	4.42e-05	0.00156	CbGpPWpGaD
Dasatinib—FYN—Disease—NPM1—lymphatic system cancer	4.26e-05	0.00151	CbGpPWpGaD
Dasatinib—JAK2—Disease—NPM1—lymphatic system cancer	4.05e-05	0.00143	CbGpPWpGaD
Dasatinib—LCK—Disease—NPM1—lymphatic system cancer	3.54e-05	0.00126	CbGpPWpGaD
Dasatinib—SRC—Disease—NPM1—lymphatic system cancer	3.14e-05	0.00111	CbGpPWpGaD
